Epiminder Ltd (ASX:EPI) Shares Rise as US DETECT Study Enrolment Advances

Sonal Goyal

07 October 2026 06:49 PM AEDT

Epiminder Ltd (ASX:EPI) Shares Rise as US DETECT Study Enrolment Advances

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Epiminder (ASX:EPI) traded at AUD 0.29, up 7.41% on October 7, 2026.
The Minder system has US FDA Marketing authorisation via the De Novo pathway.
Epiminder reported that the US DETECT study reached its 75th enrolment in September 2026.
The company raised AUD 125 million at listing to support commercialisation activities.

Epiminder Ltd is a medical-device and information-solutions company developing continuous brain-monitoring technology for epilepsy and other seizure disorders. Its core product, Minder, is a minimally invasive system designed to record electrographic brain activity over extended periods while patients continue normal daily activities. Epiminder shares moved higher on October 7, 2026. At the time of writing, Epiminder (ASX:EPI) was trading at AUD 0.29, up 7.41% during today's session. The company is currently focused on US commercial preparation, clinical evidence generation and the development of its next-generation device.

Company Business

Minder is designed to provide clinicians with long-duration brain-activity data that can support assessment of seizure burden and treatment response. Epiminder is headquartered in Melbourne and also has operations in the United States. The company received FDA marketing authorisation for Minder through the De Novo pathway, giving it a regulatory basis for US commercialisation. The DETECT study is an important part of building experience with implantation, care pathways and real-world use ahead of broader commercial activity.

Recent Development

During 2026, Epiminder reported several enrolment milestones in the US DETECT study. The study reached 25 enrolments in June, 50 in July and 75 by September. Earlier in the year, the company also reported the first US implant of the Minder system. Epiminder raised AUD 125 million at the time of its ASX listing in December 2025 and has been using the Capital to support the DETECT program, development of the G1 Minder device and commercial-readiness activities.

Financial Performance and Sector Context

At the first-half FY26 result, Epiminder said it had sufficient cash resources to fund Investment priorities well into 2028, based on its then-current plans. It also highlighted a Medicare reimbursement determination for 2026 at US$27,700 for the Minder device, which supported the company's assumed US selling-price framework. As an early commercial-stage medical-device company, Epiminder's near-term financial profile is still dominated by development and market-entry spending rather than established product revenue. Cash use can vary with implant volumes, study-centre activity and device development.

Risks to Consider

Key risks include slower patient enrolment, surgical adoption barriers, reimbursement changes, product-development delays and the cost of building a commercial infrastructure before Revenue reaches scale. Medical-device Manufacturing and post-market regulatory requirements also remain important as activity expands.

What to Watch Next

Investors may monitor further DETECT enrolment, implant outcomes, G1 device development, reimbursement developments, cash expenditure and the timing of broader US commercialisation. Updates on clinical workflow and the number of participating centres will help show whether the company is building the infrastructure needed for wider adoption.

Key Insights

Epiminder has progressed from ASX listing into active US clinical deployment of the Minder system during 2026. The shares were higher on October 7, 2026, while the longer-term assessment remains centred on DETECT execution, reimbursement, product development and cash discipline. These milestones will help determine how quickly the company can move from clinical deployment toward commercial scale.

FAQs

Q:What was Epiminder's share price on October 7, 2026?

A:EPI was trading at AUD 0.29, up 7.41% during the session at the time of writing.

Q:What is the Minder system?

A:Minder is a minimally invasive device for long-term monitoring of electrographic brain activity in people with epilepsy.

Q:How far has the DETECT study progressed?

A:Epiminder reported that the study reached its 75th enrolment in September 2026.

Q:Does Minder have US regulatory clearance?

A:Yes. Minder has FDA marketing authorisation through the De Novo pathway.

Q:What should investors monitor next?

A:DETECT enrolment, implant outcomes, reimbursement, G1 development, cash use and commercialisation timing are key areas to follow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.